Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
A biopharmaceutical company developing therapies for liver diseases, including NASH.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to stop liver failure in NASH patients Results expected Dec 2026 (estimated) May already have reported ↗
- New pill shows promise for fatty liver in major trial Results expected Mar 2027 (estimated) May already have reported ↗
-
New drug aims to stop liver failure in NASH patients
Disease control OngoingThis phase 3 study tests whether a daily pill called resmetirom can prevent serious liver events like liver failure, need for transplant, or bleeding in people with NASH cirrhosis. About 845 adults with well-compensated cirrhosis will receive either the drug or a placebo. The goa…
Phase 3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
Disease control OngoingThis Phase 3 trial tests whether the drug resmetirom (MGL-3196) can reverse liver scarring (fibrosis) and stop NASH from progressing to cirrhosis or liver failure. About 1,759 adults with NASH and liver fibrosis will receive either resmetirom or a placebo daily for up to 54 month…
Phase 3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill shows promise for fatty liver in major trial
Disease control OngoingThis study tests a daily pill called resmetirom in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if it safely reduces liver fat and cholesterol over 52 weeks. About 810 adults who completed earlier related studies are taking part. This is a long-term t…
Phase 3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC